The goal of this clinical trial is to learn if the use of the sedative remimazolam improves the safety of patients having cataract surgery by decreasing the number of sedation-related complications during and after surgery, and shortening post-surgical cognitive recovery time.
Phase:
PHASE4
Details
Lead Sponsor:
Fred E, Shapiro
Collaborators:
Eagle Pharmaceuticals, Inc. Massachusetts Eye and Ear Infirmary